Clinical trial · Observational
Radiomic Assessment in NSCLC: Correlation Between Multiparametric Imaging Biomarkers and Genetic Biomarkers
NCT01585545CI-TRIAL-00058265unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to evaluate relationships between multiparametric imaging biomarkers and genetic analysis in NSCLC patients.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lung Cancer | Malignant Lung Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (1)
- label
- patients with NSCLC
Primary outcomes (1)
- measure
- Functional and genomic profiling of lung cancer
- timeFrame
- five years
- description
- Prognostic stratification will be evaluated using following parameters: 1. Quantitative and qualitative parameters from CT, PET, MRI 2. Genomic data of lung cancer samples
Secondary outcomes (2)
- measure
- Relationship between genomic and multiparametric imaging profiling
- timeFrame
- five years
- description
- We will evaluate if certain relationship exists between changes in multiparametric imaging markers from CT, PET, MRI and genomic informations of NSCLC.
- measure
- Precise prediction of pulmonary function such as ventilation and perfusion after the lung resection.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 20 Years
Show eligibility criteria text
Inclusion Criteria: * Suspected lung cancer on chest CT or histologically proven NSCLC * Participant is being considered for the conventional/neoadjuvant/targeted chemotherapy or surgery * At least one measurable primary or other intrathoracic lesion \>= 2cm, according to RECIST * Performance status of 0 to 2 on the ECOG scale * Age 20 years or older * Able to tolerable PET/CT and CT imaging required by protocol * Able to undergo percutaneous needle biopsy before and after chemotherapy * Able to give study-specific informed consent Exclusion Criteria: * Poorly controlled diabetes * Contraindication for CT contrast agent
References
Publications (0)
Data not yet available
No reference posted for this study.